期刊文献+

卡维地洛治疗慢性心力衰竭疗效的系统评价 被引量:1

Systematic Review of Therapeutic Efficacy of Carvedilol in the Treatment of Chronic Heart Failure
原文传递
导出
摘要 目的:对卡维地洛治疗慢性心力衰竭相关文献进行系统评价,为临床用药提供参考。方法:查阅中文已公开发表的有关卡维地洛治疗慢性心力衰竭的临床随机对照试验文献,以左心室射血分数(LVEF)和心率为评价指标,采用Cochrane协作网的软件RevMan4.2进行Meta分析。结果:有5项研究纳入Meta分析,总样本数为459。LVEF有效率差值为7.67,95%可信区间(5.54,9.79),位于无效线右侧,具有统计学意义。心率有效率差值为-9.96,95%可信区间(-13.97,-5.96),位于无效线左侧,具有统计学意义。结论:卡维地洛治疗慢性心力衰竭对LVEF和心率均有改善作用。 OBJECTIVE: To evaluate relevant literatures about carvedilol in the treatment of chronic heart failure systematically, and to provide reference for clinical drug use. METHODS: Published literatures of randomized controlled trials about carvedilolin in the treatment of chronic heart failure were reviewed. Using LVEF and heart rate as evaluation index, Meta-analysis was conducted using RevMan 4.2 software on the Cochrane pensonnel network. RESULTS: There were five studies included in Meta-analysis, and the total number of sample was 459. Left ventricular ejection fraction efficient difference was 7.67 [95% confidence interval (5.54, 9.79)] located on the right side of inefective line, which had statistical significance. Heart rate efficient difference was -9.96 [95% confidence interval (-13.97,-5.96)] located on the left side of ineffective line, which had statistical significance. CONCLUSION: Carvedilol for chronic heart failure can improve left ventricular ejection fraction and heart rate.
出处 《中国药房》 CAS CSCD 北大核心 2011年第24期2276-2278,共3页 China Pharmacy
关键词 卡维地洛 慢性心力衰竭 META分析 Carvedilol Chronic heart failure Meta-analysis
  • 相关文献

参考文献7

二级参考文献29

  • 1[1]Packer M.β-blockade in heart failure-basic concepts and clinical results[J].Am J Hypertens,1998,11(1Pt2):23-27.
  • 2[2]Frishman WH.Carvedilol[J].N Engl J Med,1998,339(24):1759-1765.
  • 3[3]Ustralia/New-Zealand Heart Failure Research Collaborative Group.Randomised,placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease[J].Lancet,1997,349(2):375-380.
  • 4[4]Colucci WS,Packer M,Bristow MR,et al.Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure.US Carvedilol Heart Failure Study Group[J].Circulation,1996,94(11):2800-2806.
  • 5[5]Packer M,Colucci WS,Sacker-Bernstein JD,et al.Doubleblind,placebo-controlled Study of the effects of earvedilol in patients with moderate to severe heart failure,the PRECISE trial[J].Circulation,1996,94(11):2793-2799.
  • 6Azevedo ER, et al. Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity[J ]. Circulation, 2001,104: 2194 - 2199.
  • 7Goldstein S, et al, MERIT-HF Study Group. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study[J] .J Am Call Cardial,2001,38:932 - 938.
  • 8Beta-Blocker Evaluation of Survival Trial Investigation. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure[J]. N Engl J Mtd ,2001,344:1659 - 1667.
  • 9Heart Failure Society of America. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dys-function-pharmacotherapy approaches[J].Pharmacotherapy,2000,20 : 495 - 522.
  • 10Packer M, et al.β-adrenergic blockade in chronic heart failure: principles, progress and practice[J]. J Proin Cargiovas Dis, 1998,41(suppl 1 ) : 398.

共引文献87

同被引文献10

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部